Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 972,150 | 746,996 | 755,127 | 785,414 | 694,381 |
| Marketable Securities | 252,201 | 299,584 | 318,683 | 340,431 | 476,577 |
| Receivables | 691,232 | 637,163 | 633,704 | 572,498 | 610,222 |
| Inventories | 1,183,621 | 1,137,982 | 1,107,183 | 1,032,159 | 975,546 |
| Other current assets | 160,426 | 163,287 | 141,391 | 224,806 | 193,391 |
| TOTAL | $3,259,630 | $2,985,012 | $2,956,088 | $2,955,308 | $2,950,117 |
| Non-Current Assets | |||||
| PPE Net | 1,052,898 | 1,060,425 | 1,066,133 | 1,067,156 | 1,067,278 |
| Investments And Advances | 557,083 | 620,551 | 611,135 | 548,002 | 385,777 |
| Intangibles | 461,732 | 475,852 | 490,900 | 498,675 | 506,542 |
| Other Non-Current Assets | 1,735,778 | 1,730,833 | 1,717,347 | 1,689,022 | 1,653,458 |
| TOTAL | $3,807,491 | $3,887,661 | $3,885,515 | $3,802,855 | $3,613,055 |
| Total Assets | $7,067,121 | $6,872,673 | $6,841,603 | $6,758,163 | $6,563,172 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 494,837 | 494,357 | 493,877 | 493,398 | N/A |
| Accounts payable and accrued liabilities | 572,500 | 593,543 | 683,147 | 669,825 | 597,231 |
| TOTAL | $1,067,337 | $1,087,900 | $1,177,024 | $1,163,223 | $597,231 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 713,485 | 710,957 | 713,030 | 698,043 | 1,183,114 |
| TOTAL | $713,485 | $710,957 | $713,030 | $698,043 | $1,183,114 |
| Total Liabilities | $1,780,822 | $1,798,857 | $1,890,054 | $1,861,266 | $1,780,345 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 190,383 | 189,880 | 188,676 | 188,368 | 188,175 |
| Common Shares | 190 | 190 | 189 | 188 | 188 |
| Retained earnings | -425,718 | -532,892 | -621,554 | -641,929 | -682,307 |
| Other shareholders' equity | 15,126 | -12,746 | -38,648 | -4,136 | -29,010 |
| TOTAL | $5,286,299 | $5,073,816 | $4,951,549 | $4,896,897 | $4,782,827 |
| Total Liabilities And Equity | $7,067,121 | $6,872,673 | $6,841,603 | $6,758,163 | $6,563,172 |